Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical trials in oncology: specific methodology problems].

E Baumelou1, D Méry-Mignard, J P Lehner

  • 1CHU, Lille, France.

Therapie
|November 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2012
Same author

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2005
Same author

A phase I clinical and pharmacokinetic study of capecitabine (Xeloda) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours.

British journal of cancer·2005
Same author

A phase I-II, dose-escalating trial of ZD9331 in combination with irinotecan (CPT11) in previously pretreated metastatic colorectal cancer patients.

Bulletin du cancer·2005
Same author

Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2004
Same author

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Coordinated clinical trials are essential for oncology patient benefit. This includes registering adverse events (AE), using epidemiological data, and adapting trial designs for new therapies and specific populations like children and the elderly.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Pharmacovigilance

Context:

  • Clinical benefit in oncology requires coordinated experimental trials.
  • Current assessment methods need enhancement for new therapeutic agents and diverse patient groups.
  • Regulatory frameworks for gene and cell therapy trials have evolved.

Purpose:

  • To establish consensus on best practices for clinical trial design and assessment in oncology.
  • To address the unique challenges of evaluating novel antiproliferative agents and therapies in specific populations.
  • To improve the registration and long-term assessment of adverse events (AE).

Summary:

  • Clinical trials must register acute adverse events (AE) and utilize epidemiological data for long-term assessment.

Related Experiment Videos

  • New antiproliferative agents require evaluation based on active dose and early biological efficacy criteria, not just maximal tolerable dose.
  • Special considerations are needed for gene/cell therapy trials, post-marketing surveillance, and patient populations including the elderly and children.

    • Impact:

    • Improved evaluation of anticancer agents, particularly novel therapies and in vulnerable populations.
    • Enhanced patient safety through systematic monitoring of adverse events.
    • Establishment of a comprehensive registry of oncology clinical trials.